Document is current
Any future updates will be listed below
-
Authors
Blair, Alex B.
Radomski, Shannon N.
Chou, Joanne
Liu, Mengyuan
Howell, Thomas C.
Park, Wungki
O’Reilly, Eileen M.
Zheng, Lei
Balachandran, Vinod P.
Wei, Alice C.
Kingham, T. Peter
D’Angelica, Michael I.
Drebin, Jeffrey
Zani, Sabino
Blazer, Dan III
Burkhart, Richard A.
Burns, William R. III
Lafaro, Kelly J.
Allen, Peter J.
Jarnagin, William R.
Lidsky, Michael E.
He, Jin
Soares, Kevin C. https://orcid.org/0000-0002-0406-017X
- License Information
-
More Information
Article History
First Online: 18 June 2025
Disclosure
: Eileen O'Reilly received research funding to her institution from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, Agenus. She provided consulting/DSMB for Arcus, Ability Pharma, Alligator BioSciences, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicines, Regeneron, Merus Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) Servier (spouse). Lei Zheng receives grant support from Bristol-Myers Squibb, Merck, and Astrazeneca; is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Amberstone, Tavotek Lab, Duo Oncology, ClinicalTrial Options, LLC, and Mingruizhiyao; and holds shares at Amberstone, Alphamab, Cellaration, and Mingruizhiyao. Alice Wei provides consulting for Histosonics and received institutional clinical trial funding from Ipsen. Memorial Sloan Kettering has institutional financial interests relative BioNTech, Epistem Prognostics, and Clarity Pharmaceuticals.
